UK markets open in 6 hours 47 minutes
  • NIKKEI 225

    27,001.52
    0.00 (0.00%)
     
  • HANG SENG

    20,470.06
    -247.18 (-1.19%)
     
  • CRUDE OIL

    109.40
    -0.89 (-0.81%)
     
  • GOLD FUTURES

    1,852.20
    +4.40 (+0.24%)
     
  • DOW

    31,880.24
    +618.34 (+1.98%)
     
  • BTC-GBP

    23,221.22
    -1,011.21 (-4.17%)
     
  • CMC Crypto 200

    653.64
    -21.24 (-3.15%)
     
  • ^IXIC

    11,535.27
    +180.66 (+1.59%)
     
  • ^FTAS

    4,150.28
    +66.44 (+1.63%)
     

Pharvaris to Participate in BofA Securities 2022 Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Pharvaris N.V.
Pharvaris N.V.

ZUG, Switzerland, May 05, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building on its deep-seated roots in hereditary angioedema (HAE), today announced that management will present at the BofA Securities 2022 Healthcare Conference taking place in Las Vegas, NV from May 10 – 12, 2022.

Pharvaris’ presentation will take place at 10:00 AM PDT (7:00 PM CEST) on Thursday, May 12, 2022. A live webcast of the presentation will be available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations. A replay will be available on Pharvaris’ website for 30 days following the presentation.

About Pharvaris
Pharvaris is a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building on its deep-seated roots in HAE. By directly targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all sub-types of HAE more effective and convenient alternatives to treat attacks, both on-demand and prophylactically. The company brings together the best talent in the industry with deep expertise in rare diseases and HAE. For more information, visit https://pharvaris.com/.

Contacts
Pharvaris
Maryann Cimino
Director of Corporate Relations
maryann.cimino@pharvaris.com
+1-617-710-7305

Investors
Sarah McCabe
sarah.mccabe@sternir.com
+1-212-362-1200

Media
Scott Stachowiak, Russo Partners, LLC
Scott.Stachowiak@russopartnersllc.com
+1-646-942-5630



Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting